The DTX3L Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the DTX3L gene in the A2780 human ovarian carcinoma cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, producing a mixed population of cells lacking functional DTX3L expression, thereby enabling robust functional studies without clonal selection bias.
The A2780 host cell line is a well-established epithelial ovarian cancer model derived from tumor tissue of an untreated patient. These adherent cells retain key characteristics of high-grade serous ovarian carcinoma, including relevant oncogenic signaling networks and genomic instability features, making them a suitable background for investigating molecular mechanisms underlying ovarian cancer pathogenesis.
DTX3L encodes an E3 ubiquitin-protein ligase that functions as a critical regulator of both Notch signaling and the DNA damage response. DTX3L promotes ubiquitination and subsequent proteasomal degradation of target proteins, including the Notch intracellular domain (NICD) and PARP1. Upstream, DTX3L is activated by Notch receptor (NOTCH1) engagement and DNA damage signals, and it interacts directly with PARP1 and E3 ligase complex components to modulate substrate specificity. Through these interactions, DTX3L fine-tunes Notch-mediated transcriptional outputs and maintains genomic stability by controlling the turnover of DNA repair factors.
In the A2780 ovarian carcinoma context, DTX3L disruption provides a powerful tool for dissecting its dual role in oncogenic signaling and cellular stress responses. The knockout model facilitates the examination of how loss of DTX3L-mediated ubiquitination alters NICD stability and Notch target gene expression, potentially affecting tumor cell proliferation, apoptosis, and therapy resistance. Moreover, compromised DNA repair regulation may enhance sensitivity to DNA-damaging agents, offering insight into treatment vulnerabilities in ovarian cancer.
This polyclonal knockout cell population is ideal for a range of research applications, including detailed ubiquitination assays to monitor substrate modification, western blotting for Notch pathway components and DNA damage markers (such as phosphorylated H2AX), co-immunoprecipitation to probe DTX3L interactions, and flow cytometry for cell cycle and apoptosis analyses. Additionally, drug sensitivity screens can evaluate response to chemotherapeutics and PARP inhibitors. For further information or to order, contact Ascent Research.
